FDA Panel Okays Purdue's Newer OxyContin, But Is Still Hung Up On Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee members said a newer formulation of OxyContin may deter misuse, but its safety is unclear.